Long-Term Open-Label Extension Study of Oral Levosimendan
NCT07436689
·
clinicaltrials.gov ↗
PHASE3
Phase
ENROLLING_BY_INVITATION
Status
800
Enrollment
INDUSTRY
Sponsor class
Conditions
Pulmonary Hypertension Associated With HFpEF
Interventions
DRUG:
TNX-103
Sponsor
Tenax Therapeutics, Inc.